Tech Company Financing Transactions
Avanzanite Bioscience Funding Round
MVM Life Science Partners and private investors participated in a $37 million Series A funding round for Avanzanite Bioscience. The round was announced on 11/18/2025.
Transaction Overview
Company Name
Announced On
11/18/2025
Transaction Type
Venture Equity
Amount
$37,000,000
Round
Series A
Investors
MVM Life Science Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate the expansion of its pan-European infrastructure and further enhance both current and future rare disease product launches.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Strawinskylaan 3051
Amsterdam, 1077ZX
The Netherlands
Amsterdam, 1077ZX
The Netherlands
Phone
Undisclosed
Website
Email Address
Overview
Founded by biopharmaceutical executives, Adam Plich and Anant Murthy, Avanzanite is on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond. Derived from the word 'Tanzanite' -- one of the rarest and most underappreciated gemstones on earth -- Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adam Plich
Browse more venture capital transactions:
Prev: 11/18/2025: Ursa Major venture capital transaction
Next: 11/18/2025: Orion venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to record every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs